Roche secures Zealand obesity drug candidate for up to $5.3 billion
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
pharmaphorum18h
Roche builds in obesity with $5.3bn Zealand licensing deal
Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...
NovoNordisk stock falls on Roche-Zealand pact; Jefferies cuts target
Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).